Home・Lista de Ações・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Abrir

SetorSaúde

49.74 9.61

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

44.21

Máximo

48.35

Indicadores-chave
By Trading Economics
Rendimento	2.8M -13M
Vendas	-15M 151M
EPS	0.07
Margem de lucro	-8.93
Funcionários	1,178
EBITDA	19M -937K

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	-5.7% downside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	3.2B 6B
Abertura anterior	40.13
Fecho anterior	49.74

Sentimento de Notícias

By Acuity

100%

329 / 340 Ranking em Healthcare

10X Genomics Inc (Class A) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5 de ago. de 2026, 19:26 UTC

Correlated Moves

News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3 de ago. de 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31 de jul. de 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30 de jul. de 2026, 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29 de jul. de 2026, 19:27 UTC

Macro Event

News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28 de jul. de 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27 de jul. de 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24 de jul. de 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 de jul. de 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 de jul. de 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 de jul. de 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 de jul. de 2026, 19:16 UTC

News

Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Comparação entre Pares

Variação de preço

10X Genomics Inc (Class A) Previsão

Preço-alvo

By TipRanks

-5.7% parte inferior

Previsão para 12 meses

Média 43 USD -5.7%

Máximo 53 USD

Mínimo 23 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para 10X Genomics Inc (Class A) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para 10X Genomics Inc (Class A) - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.